Riluzole for Amyotrophic Lateral Sclerosis Treatment

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1487-000

Question

  1. What is the clinical effectiveness of riluzole for patients living with ALS compared to alternative pharmacological therapies?
  2. What is the clinical effectiveness of riluzole for patients living with ALS compared to no treatment?
  3. What is the cost-effectiveness of riluzole for patients living with ALS?
  4. What are the evidence-based guidelines regarding the use of riluzole for the treatment of patients with ALS?

Key Message

  • Treatment with riluzole may provide clinical benefits for patients with amyotrophic lateral sclerosis, including longer survival time, reduced risk of disease progression, and minor reversible adverse events, compared to no treatment with riluzole or a placebo.
  • We did not find any studies meeting our selection criteria on the clinical effectiveness of riluzole for patients with amyotrophic lateral sclerosis compared to alternative pharmacological therapies.
  • Riluzole may be cost-effective at generic drug costs for patients with amyotrophic lateral sclerosis. Evidence supporting this finding is limited, and further research is required to inform decision-making.
  • Riluzole is recommended for the treatment of amyotrophic lateral sclerosis, except for patients with progressive muscular atrophy, primary lateral sclerosis, or hereditary spastic paraplegia, and should be initiated promptly following disease diagnosis.
  • A patient with lived experience of riluzole treatment for amyotrophic lateral sclerosis was involved in this report. They identified outcomes that are important to patients, including slowing the progression of amyotrophic lateral sclerosis and minimal side effects from the medication.